Optimal and Actual Rates of Stereotactic Ablative Body Radiotherapy (SABR) Utilisation for Primary Lung Cancer in Australia

Overview

Journal Clin Transl Radiat Oncol

Specialty Oncology

Date 2022 Mar 14

PMID 35282142

Authors

Wsam Ghandourh

Lois Holloway

Vikneswary Batumalai

Phillip Chlap

Matthew Field

Susannah Jacob

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Radiotherapy utilisation rates considerably vary across different countries and service providers, highlighting the need to establish reliable benchmarks against which utilisation rates can be assessed. Here, optimal utilisation rates of Stereotactic Ablative Body Radiotherapy (SABR) for lung cancer are estimated and compared against actual utilisation rates to identify potential shortfalls in service provision.

Materials And Methods: An evidence-based optimal utilisation model was constructed after reviewing practice guidelines and identifying indications for lung SABR based on the best available evidence. The proportions of patients likely to develop each indication were obtained, whenever possible, from Australian population-based studies. Sensitivity analysis was performed to account for variations in epidemiological data. Practice pattern studies were reviewed to obtain actual utilisation rates.

Results: A total of 6% of all lung cancer patients were estimated to optimally require SABR at least once during the course of their illness (95% CI: 4-6%). Optimal utilisation rates were estimated to be 32% for stage I and 10% for stage II NSCLC. Actual utilisation rates for stage I NSCLC varied between 6 and 20%. For patients with inoperable stage I, 27-74% received SABR compared to the estimated optimal rate of 82%.

Conclusion: The estimated optimal SABR utilisation rates for lung cancer can serve as useful benchmarks to highlight gaps in service delivery and help plan for more adequate and efficient provision of care. The model can be easily modified to determine optimal utilisation rates in other populations or updated to reflect any changes in practice guidelines or epidemiological data.

Citing Articles

Utilisation of radiotherapy in lung cancer: A scoping narrative literature review with a focus on the introduction of evidence-based therapeutic approaches in Europe.

Corral J, Borras J, Lievens Y Clin Transl Radiat Oncol. 2024; 45:100717.

PMID: 38226026 PMC: 10788411. DOI: 10.1016/j.ctro.2023.100717.

References

Vinod S, OConnell D, Simonella L, Delaney G, Boyer M, Peters M . Gaps in optimal care for lung cancer. J Thorac Oncol. 2008; 3(8):871-9. DOI: 10.1097/JTO.0b013e31818020c3. View

Koshy M, Malik R, Mahmood U, Husain Z, Sher D . Stereotactic body radiotherapy and treatment at a high volume facility is associated with improved survival in patients with inoperable stage I non-small cell lung cancer. Radiother Oncol. 2015; 114(2):148-54. DOI: 10.1016/j.radonc.2014.12.004. View

Postmus P, Kerr K, Oudkerk M, Senan S, Waller D, Vansteenkiste J . Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(suppl_4):iv1-iv21. DOI: 10.1093/annonc/mdx222. View

Walters S, Maringe C, Coleman M, Peake M, Butler J, Young N . Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007. Thorax. 2013; 68(6):551-64. DOI: 10.1136/thoraxjnl-2012-202297. View

Zelman Lewis S, Diekemper R, Addrizzo-Harris D . Methodology for development of guidelines for lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143(5 Suppl):41S-50S. DOI: 10.1378/chest.12-2344. View

Palma D, Visser O, Lagerwaard F, Belderbos J, Slotman B, Senan S . Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol. 2010; 28(35):5153-9. DOI: 10.1200/JCO.2010.30.0731. View

Lievens Y, Grau C . Health economics in radiation oncology: introducing the ESTRO HERO project. Radiother Oncol. 2012; 103(1):109-12. DOI: 10.1016/j.radonc.2011.12.026. View

Wouters M, Siesling S, Jansen-Landheer M, Elferink M, Belderbos J, Coebergh J . Variation in treatment and outcome in patients with non-small cell lung cancer by region, hospital type and volume in the Netherlands. Eur J Surg Oncol. 2010; 36 Suppl 1:S83-92. DOI: 10.1016/j.ejso.2010.06.020. View

Vinod S . International patterns of radiotherapy practice for non-small cell lung cancer. Semin Radiat Oncol. 2015; 25(2):143-50. DOI: 10.1016/j.semradonc.2014.11.001. View

10.

Andrews J, Guyatt G, Oxman A, Alderson P, Dahm P, Falck-Ytter Y . GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 2013; 66(7):719-25. DOI: 10.1016/j.jclinepi.2012.03.013. View

11.

Akhtar-Danesh G, Finley C, Seow H, Shakeel S, Akhtar-Danesh N . Change in treatment modality and trends in survival among stage I non-small cell lung cancer patients: a population-based study. J Thorac Dis. 2020; 12(9):4670-4679. PMC: 7578458. DOI: 10.21037/jtd-20-1387. View

12.

Asli L, Kvaloy S, Jetne V, Myklebust T, Levernes S, Tveit K . Utilization of radiation therapy in Norway after the implementation of the national cancer plan--a national, population-based study. Int J Radiat Oncol Biol Phys. 2014; 90(3):707-14. DOI: 10.1016/j.ijrobp.2014.06.059. View

13.

Li W, Visser O, Ubbink D, Klomp H, Kloek J, de Mol B . The influence of provider characteristics on resection rates and survival in patients with localized non-small cell lung cancer. Lung Cancer. 2008; 60(3):441-51. DOI: 10.1016/j.lungcan.2007.10.029. View

14.

Shafiq J, Hanna T, Vinod S, Delaney G, Barton M . A Population-based Model of Local Control and Survival Benefit of Radiotherapy for Lung Cancer. Clin Oncol (R Coll Radiol). 2016; 28(10):627-38. DOI: 10.1016/j.clon.2016.05.006. View

15.

Kennedy W, Gabani P, Nikitas J, Robinson C, Bradley J, Roach M . Repeat stereotactic body radiation therapy (SBRT) for salvage of isolated local recurrence after definitive lung SBRT. Radiother Oncol. 2019; 142:230-235. PMC: 7655115. DOI: 10.1016/j.radonc.2019.08.010. View

16.

Bezjak A, Paulus R, Gaspar L, Timmerman R, Straube W, Ryan W . Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial. J Clin Oncol. 2019; 37(15):1316-1325. PMC: 6524984. DOI: 10.1200/JCO.18.00622. View

17.

Batumalai V, Shafiq J, Gabriel G, Hanna T, Delaney G, Barton M . Impact of radiotherapy underutilisation measured by survival shortfall, years of potential life lost and disability-adjusted life years lost in New South Wales, Australia. Radiother Oncol. 2018; 129(2):191-195. DOI: 10.1016/j.radonc.2018.06.026. View

18.

Phillips I, Sandhu S, Luchtenborg M, Harden S . Stereotactic Ablative Body Radiotherapy Versus Radical Radiotherapy: Comparing Real-World Outcomes in Stage I Lung Cancer. Clin Oncol (R Coll Radiol). 2019; 31(10):681-687. DOI: 10.1016/j.clon.2019.07.013. View

19.

Kowalchuk R, Waters M, Richardson K, Spencer K, Larner J, Kersh C . Stereotactic Body Radiation Therapy for Salvage Treatment of Recurrent Non-Small Cell Lung Cancer. Pract Radiat Oncol. 2020; 10(6):e475-e484. DOI: 10.1016/j.prro.2020.05.005. View

20.

Haasbeek C, Palma D, Visser O, Lagerwaard F, Slotman B, Senan S . Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands. Ann Oncol. 2012; 23(10):2743-2747. DOI: 10.1093/annonc/mds081. View